IRIS: Insulin Resistance Intervention After Stroke Trial

E-mail Print PDF
Insulin Resistance Intervention After Stroke Trial.
Phase III, randomized, double-blind, placebo controlled trial. The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke. The IRIS trial will test a new treatment strategy based on evidence linking insulin resistance to increased risk for stroke and other vascular diseases. Insulin resistance is a condition in which insulin, a normal human hormone, does not work effectively because the body is resistant to its effects. This condition can lead to diabetes and is thought to cause blood vessel disease, including stroke and heart attack, in patients with and without diabetes.A total of 3136 participants shall be recruited.
Last Updated ( Monday, 12 October 2015 11:28 )  

Members Login

ASTN Latest news

Top Views